British Patient Capital has made a USD20 million commitment into Balderton Capital VIII, which has closed at USD600 million.
The fund is Balderton’s largest ever early-stage fund and will look to invest in leading-edge technologies across the UK and Europe, building on the team’s expertise in backing companies from seed to growth stage. Portfolio companies from previous funds include fintech and insuretech unicorns Revolut and Zego, as well as AI technology companies Healx and Cleo, which have reached growth status since the initial investment.
This commitment follows British Patient Capital’s previous investments in Balderton Capital VI, Balderton Capital VII and, more recently, Balderton Capital Growth I, which closed in June 2021.
